Form 4: Pacira BioSciences Director Laura Brege Granted Equity Compensation

Pacira BioSciences, Inc. director Laura Brege was granted 6,163 restricted stock units and 11,279 stock options, aligning her interests with shareholders.

Summary

• Laura Brege, a Director at Pacira BioSciences, Inc. (PCRX), acquired 6,163 shares of common stock in the form of restricted stock units (RSUs) on June 11, 2025.
• These RSUs were granted at a price of $0 and will vest on June 11, 2026, contingent upon her continuous service with the issuer.
• Following this transaction, Ms. Brege beneficially owns a total of 23,715 shares of common stock.
• Additionally, Ms. Brege acquired 11,279 stock options on June 11, 2025, with an exercise price of $24.34 per share.
• These stock options also vest and become exercisable on June 11, 2026, provided her continuous service, and have an expiration date of June 11, 2035.
• The acquisition of both the RSUs and stock options was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it reflects standard, ongoing director compensation, which aligns insider interests with shareholders and indicates continued commitment to the company.

Positives

• The grant of restricted stock units and stock options to Director Laura Brege aligns her financial interests directly with the long-term performance and shareholder value of Pacira BioSciences, Inc.
• The equity compensation package serves as an incentive for Ms. Brege to remain in continuous service with the company through the vesting dates, ensuring stability in governance.

Risks

• The vesting of both the restricted stock units and stock options is contingent upon Laura Brege's continuous service with Pacira BioSciences, Inc. through June 11, 2026, meaning the benefits are not guaranteed if her service ceases before this date.

Future Outlook

The equity grants to Director Laura Brege, with vesting tied to continuous service through June 11, 2026, indicate an expectation of her ongoing contribution to the company's governance and strategic direction for at least the next year.

Industry Context

The granting of equity compensation, such as restricted stock units and stock options, to directors is a standard practice across the biotechnology and pharmaceutical industries. This practice is widely used to attract and retain qualified board members and to align their long-term interests with those of the company's shareholders.

Related Party Transactions

• The transaction involves the grant of equity compensation (restricted stock units and stock options) from Pacira BioSciences, Inc. to Laura Brege, a director of the company, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The equity grants align the director's long-term interests with those of the shareholders, potentially fostering decisions that enhance shareholder value.
• Employees: No direct impact on general employees is indicated by this filing, though it reflects standard compensation practices for leadership.

Next Steps

• Laura Brege's continued service with Pacira BioSciences, Inc. through June 11, 2026, for the vesting of her restricted stock units and stock options.

Key Dates

Keywords

SEC Form 4, insider transaction, restricted stock units, stock options, equity compensation, director compensation, Pacira BioSciences, PCRX, corporate governance